Trials / Enrolling By Invitation
Enrolling By InvitationNCT07135219
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Immunoglobulin A Nephropathy
- Status
- Enrolling By Invitation
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with IgAN.
Detailed description
An Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients with Immunoglobulin A Nephropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Biological: cizutamig | Cizutamig will be dosed according to the protocol. |
Timeline
- Start date
- 2025-07-16
- Primary completion
- 2025-12-01
- Completion
- 2027-01-01
- First posted
- 2025-08-22
- Last updated
- 2025-08-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07135219. Inclusion in this directory is not an endorsement.